Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Manabu Hirai"'
Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants
Autor:
Hidetoshi, Shimizu, Yukiko, Nishimura, Youichi, Shiide, Makoto, Akimoto, Hideaki, Matsuda, Yuichiro, Kato, Manabu, Hirai
Publikováno v:
Clinical Therapeutics. 44:1552-1565
The safety and efficacy of intravenous edaravone, a neuroprotectant used for the treatment of amyotrophic lateral sclerosis (ALS), have been shown in clinical trials. An oral suspension of edaravone has been developed, but the food effect on its phar
Autor:
Hidetoshi, Shimizu, Yukiko, Nishimura, Youichi, Shiide, Masaki, Ueda, Shoko, Yokota, Yuichiro, Kato, Manabu, Hirai
Publikováno v:
Clinical Pharmacology in Drug Development. 12:77-84
Intravenous edaravone is used to treat patients with amyotrophic lateral sclerosis. This randomized, open-label, two-way crossover, single-dose phase 1 study compared the relative bioavailability of a newly developed edaravone oral suspension when ad
Autor:
Angela Genge, Gary Pattee, Gen Sobue, Philippe Couratier, Daniel Selness, Sachin Bidani, Manabu Hirai, Takeshi Sakata, Alejandro Salah, Stephen Apple
Publikováno v:
Monday, April 24.
Autor:
Angela Genge, Gary L. Pattee, Gen Sobue, Masashi Aoki, Hiide Yoshino, Philippe Couratier, Christian Lunetta, Susanne Petri, Daniel Selness, Sachin Bidani, Manabu Hirai, Takeshi Sakata, Alejandro Salah, Stephen Apple, Art Wamil, Alexander Kalin, Carlayne E. Jackson
Publikováno v:
MusclenerveREFERENCES.
An intravenous (IV) formulation of edaravone has been shown to slow the rate of physical functional decline in amyotrophic lateral sclerosis (ALS). An oral suspension formulation of edaravone was recently approved by the United States Food and Drug A
Autor:
Kazuoki Kondo, Yoshinobu Nakamaru, Manabu Hirai, Yukiko Nishimura, Kaori Yoshida, Munetomo Matsuda, Yuichiro Kato, Hidetoshi Shimizu, Youichi Shiide
Publikováno v:
Clinical Pharmacology in Drug Development
The neuroprotective agent edaravone is an intravenous treatment for amyotrophic lateral sclerosis. As intravenous administration burdens patients, orally administered treatments are needed. This phase 1, open‐label, single‐dose crossover study in
Publikováno v:
Neurology and Clinical Neuroscience. 8:261-269
Publikováno v:
Journal of Clinical Biochemistry and Nutrition
Edaravone is a low-molecular-weight antioxidant drug targeting peroxyl radicals among many types of reactive oxygen species. Because of its amphiphilicity, it scavenges both lipid- and water-soluble peroxyl radicals by donating an electron to the rad
Autor:
Manabu Hirai, Masayuki Hino, Takafumi Nakao, Hideya Ueda, Takahisa Yamane, Hideo Koh, Takahiko Nakane, Masahiro Yoshida, Erina Sakamoto, Kiyoyuki Hagihara, Takeshi Inoue, Mirei Horiuchi, Hiroshi Kanashima
Publikováno v:
European Journal of Haematology. 96:409-416
Background The treatment strategy for diffuse large B-cell lymphoma (DLBCL) in elderly patients is problematic. Although several researchers have reported the effectiveness of comprehensive geriatric assessment (CGA) and the futility of curative trea
Publikováno v:
Amyotrophic lateral sclerosisfrontotemporal degeneration. 18(sup1)
There is an increasing clinical research focus on neuroprotective agents in amyotrophic lateral sclerosis (ALS). However, it is unclear how generalisable clinical study trial results are between different countries and regions.To assess similarities
Autor:
Koji Abe, Masashi Aoki, Shoji Tsuji, Yasuto Itoyama, Gen Sobue, Masanori Togo, Chikuma Hamada, Masahiko Tanaka, Makoto Akimoto, Kazue Nakamura, Fumihiro Takahashi, Kazuoki Kondo, Hiide Yoshino, Hidenao Sasaki, Ichiro Yabe, Shizuki Doi, Hitoshi Warita, Takashi Imai, Hiroaki Ito, Mitsumasa Fukuchi, Etsuko Osumi, Manabu Wada, Imaharu Nakano, Mitsuya Morita, Katsuhisa Ogata, Yuichi Maruki, Kimiko Ito, Osamu Kano, Mineo Yamazaki, Yuji Takahashi, Hiroyuki Ishiura, Mieko Ogino, Ryoko Koike, Chiho Ishida, Tsuyoshi Uchiyama, Kouichi Mizoguchi, Tomokazu Obi, Hirohisa Watanabe, Naoki Atsuta, Ikuko Aiba, Akira Taniguchi, Hideyuki Sawada, Takanori Hazama, Harutoshi Fujimura, Hirofumi Kusaka, Takenobu Kunieda, Hitoshi Kikuchi, Hidenori Matsuo, Hidetsugu Ueyama, Kazutoshi Uekawa, Masaki Ueda, Aiko Murakami, Rie Sumii, Takuya Kudou, Kazunori Morimoto, Takatomo Yoneoka, Manabu Hirai, Kouichi Sasaki, Hidetomo Terai, Tomoko Natori, Hiroshi Matsui, Kuniko Kotani, Kaori Yoshida, Tomohisa Iwasaki
Publikováno v:
The Lancet. Neurology. 16(7)
Summary Background In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS), edaravone did not show a significant difference in the Revised ALS Functional Rating Scale (ALSFRS-R) score compared with placebo. Post-hoc analysis